Perry Kim


Perry Kim, PhD

Assistant Scientific Director

Dr. Perry Kim joined CFN in July of 2014. He has over 20 years’ research and technology commercialization experience in both the private sector and academia, including working as Chief Operating Officer at AtheroChem Inc., a biopharmaceutical focused developing novel cardiovascular treatments.  Perry also has experience in the university commercialization and KTEE areas, as the Director of Commercial Development at PARTEQ Innovations, the technology commercialization arm of Queen’s University, and in the University of Ottawa’s Technology Transfer and Business Enterprise Office. He holds an adjunct assistant professor position with the Department of Biomedical and Molecular Sciences, and was formerly an assistant professor in the Department of Pharmacology and Toxicology and at the School of Environmental studies, all at Queen’s. Perry sits on the Ontario Ministry of Health and Long-Term Care’s Committee to Evaluate Drugs, which provides an essential service to the Ministry by evaluating the clinical value of drug products, interchangeability of generic drug products and cost-effectiveness of drugs through rigorous, evidence-based review. He has served as an expert panel member for Networks of Centres of Excellence and Centres of Excellence for Commercialization and Research competitions, and has also sat on CIHR Proof-of-Principle grant committees.  Perry has a PhD in Toxicology and Pharmacology from University of Toronto, and completed a postdoctoral fellowship at the Department of Molecular Genetics and Microbiology, University of New Mexico.